Delaware
|
001-34079
|
11-3516358
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
||
37000 Grand River Avenue, Suite 120
Farmington Hills, MI
|
48335
|
|||
(Address of principal executive offices)
|
(Zip Code)
|
N/A
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
OCUP
|
Nasdaq Capital Market
|
Exhibit
Number |
Exhibit Description
|
|
Press Release, dated May 7, 2021
|
OCUPHIRE PHARMA, INC.
|
||
By:
|
/s/ Mina Sooch
|
|
Mina Sooch
|
||
Chief Executive Officer
|
||
Date: May 7, 2021
|
|